| Rafael Federico Martin Garcia, MD | |
|
1451 Ave Ashford, Suite 611, San Juan, PR 00907-1511 | |
| (787) 724-3407 | |
| (787) 977-7876 |
| Full Name | Rafael Federico Martin Garcia |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 36 Years |
| Location | 1451 Ave Ashford, San Juan, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942299375 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 10,707 (Puerto Rico) | Primary |
| Entity Name | Recinto De Ciencias Medicas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295760676 PECOS PAC ID: 3678469962 Enrollment ID: O20040729001073 |
News Archive
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
According to a new report by the Institute of Medicine (IOM), despite the debacle following the drug Vioxx which was withdrawn from the market two years ago, few lessons have been learned and the Food and Drug Administration (FDA) in the U.S. still lacks the power and resources to adequately monitor the safety of newly-approved drugs.
Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share.
Telling someone to "act your age" is another way of asking him or her to behave better. Age, however, does not always bring improvements.
Agilent Technologies Inc. today signed a Memorandum of Understanding (MoU) with the Government of Malaysia through the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPHARM), an agency under the Ministry of Science, Technology and Innovation (MOSTI), to promote and develop cooperation in biotechnology.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rafael Federico Martin Garcia, MD 1451 Ave Ashford, Suite 611, San Juan, PR 00907-1511 Ph: (787) 724-3407 | Rafael Federico Martin Garcia, MD 1451 Ave Ashford, Suite 611, San Juan, PR 00907-1511 Ph: (787) 724-3407 |
News Archive
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
According to a new report by the Institute of Medicine (IOM), despite the debacle following the drug Vioxx which was withdrawn from the market two years ago, few lessons have been learned and the Food and Drug Administration (FDA) in the U.S. still lacks the power and resources to adequately monitor the safety of newly-approved drugs.
Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share.
Telling someone to "act your age" is another way of asking him or her to behave better. Age, however, does not always bring improvements.
Agilent Technologies Inc. today signed a Memorandum of Understanding (MoU) with the Government of Malaysia through the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPHARM), an agency under the Ministry of Science, Technology and Innovation (MOSTI), to promote and develop cooperation in biotechnology.
› Verified 4 days ago
Gabriela Pabon Cartagena, Dermatology Medicare: Medicare Enrolled Practice Location: 735 Ave Ponce De Leon Ste 415, San Juan, PR 00917 Phone: 787-763-9813 | |
Dr. Luz Magali Pena, MD DERMATOLOGIST Dermatology Medicare: Not Enrolled in Medicare Practice Location: 100 Calle Juan Antonio Corretjer, 407, San Juan, PR 00901 Phone: 787-724-2876 | |
Dr. Reinaldo Rosario Guardiola, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 652 Ave Munoz Rivera, Suite 3170, San Juan, PR 00918 Phone: 787-765-2305 Fax: 787-764-1359 | |
Dr. Gilberto A Solivan Acosta, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 440 San Julian, San Juan, PR 00926 Phone: 787-764-3024 Fax: 787-789-1921 | |
Maria I Martinez Colon, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: Ave. Roosevelt # 400, Suite 401, San Juan, PR 00919 Phone: 787-767-2244 Fax: 787-754-4901 | |
Dr. Pablo Ivan Almodovar, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 611 Street Pavia, Suite 201, San Juan, PR 00909 Phone: 787-727-5892 Fax: 787-268-3620 | |
Andrea Paola Caro, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: Paseo Dr. Jose Celso Barbosa, Ro Piedras Medical Center, San Juan, PR 00936 Phone: 787-758-2525 |